Roberta Marciano

Via Pansini 5
Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Retraction Note: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Retraction Note: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Journal: Breast cancer research : BCR
Published: December 22, 2025

Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Journal: British journal of cancer
Published: September 25, 2025

FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study.

FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study.

Journal: Future oncology (London, England)
Published: May 24, 2022

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.

Journal: Cancers
Published: August 30, 2021

Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.

Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.

Journal: European journal of cancer (Oxford, England : 1990)
Published: September 04, 2020

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules.

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules.

Journal: Therapeutic advances in medical oncology
Published: February 13, 2020

Mechanisms of resistance to mTOR inhibitors.

Mechanisms of resistance to mTOR inhibitors.

Journal: Critical reviews in oncology/hematology
Published: September 19, 2019

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.

Journal: Cancers
Published: June 19, 2019

From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.

From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.

Journal: Anti-cancer agents in medicinal chemistry
Published: April 20, 2017

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.

Journal: British journal of cancer
Published: March 17, 2017

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.

Journal: Scientific reports
Published: March 16, 2017

Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.

Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.

Journal: Journal of medical case reports
Published: January 31, 2017
Showing 1-12 of 21

Last Updated: 09/26/2026